CHMP Delivers More Good News For Sanofi's Dupixent
The European committee has adopted a positive opinion for Regeneron-partnered Dupixent recommending approval to include adolescents aged 12 to 17 with atopic dermatitis.
You may also be interested in...
Sales of Praluent and Eloctate disappointed but the promise of further growth for big-selling Dupixent augurs well for the French firm's future.
Lilly/Incyte’s JAK inhibitor baricitinib is the first of its class to report positive Phase III data in atopic dermatitis. But will the dosing worries of Olumiant’s rheumatoid arthritis indication spoil the party?
With Alexion's Soliris already approved, and Viela's inebilizumab within touching distance of an FDA green light, Roche is highlighting the safety profile of its investigational neuromyelitis optica spectrum disorder drug satralizumab.